化瘀通痹方联合甲氨蝶呤治疗类风湿关节炎的临床观察

Clinical observation of Huayu Tongbi prescription combined with methotrexate in the treatment of rheumatoid arthritis

目的 观察化瘀通痹方联合甲氨蝶呤治疗类风湿关节炎(RA)的临床效果。方法 60例RA患者,随机分为观察组和对照组,各30例。对照组患者给予甲氨蝶呤片治疗,观察组患者在对照组基础上加服化瘀通痹方治疗。比较两组患者的治疗效果、关节僵硬时间、关节压痛评分、关节肿胀评分及类风湿因子水平。结果 治疗后,观察组患者的治疗总有效率93.33%显著高于对照组的73.33%,差异具有统计学意义(P<0.05)。观察组患者的关节僵硬时间(25.11±9.76)min短于对照组的(35.40±18.29)min,关节压痛评分(1.98±0.44)分、关节肿胀评分(1.70±0.35)分及类风湿因子(45.88±7.93)IU/ml均显著低于对照组的(3.16±1.01)分、(3.23±0.98)分、(60.55±9.00)IU/ml,差异具有统计学意义(P<0.05)。结论 化瘀通痹方联合甲氨蝶呤治疗RA的疗效要明显优于单纯使用甲氨蝶呤治疗,并显著改善临床症状,降低类风湿因子水平,减少临床不良反应发生,值得临床推广。

Objective To observe the clinical effect of Huayu Tongbi prescription combined with methotrexate in the treatment of rheumatoid arthritis(RA). Methods A total of 60 RA patients were randomly divided into observation group and control group, with 30 cases in each group. Patients in the control group were treated with methotrexate tablets, and patients in the observation group were additionally treated with Huayu Tongbi prescription on the basis of the control group. The therapeutic effect, joint stiffness duration,joint tenderness score, joint swelling score and rheumatoid factor level were compared between the two groups.Results After treatment, the total effective rate of the observation group was 93.33%, which was significantly higher than 73.33% of the control group, and the difference was statistically significant(P<0.05). The joint stiffness duration(25.11±9.76) min of the observation group was shorter than(35.40±18.29) min of the control group;the joint tenderness score(1.98±0.44) points, joint swelling score(1.70±0.35) points and the rheumatoid factor(45.88±7.93) IU/ml of the observation group were significantly lower than(3.16±1.01) points,(3.23±0.98) points, and(60.55±9.00) IU/ml of the control group;all the differences were statistically significant(P<0.05).Conclusion Huayu Tongbi prescription combined with methotrexate has better efficacy in the treatment of RA than that of methotrexate alone, which can significantly improve clinical symptoms, reduce the level of rheumatoid factor, and reduce the occurrence of clinical adverse reactions, which is worthy of clinical promotion.